Atypical Antipsychotics in Children with Pervasive Developmental Disorders

  title={Atypical Antipsychotics in Children with Pervasive Developmental Disorders},
  author={Benjamin Chavez and Mapy Ch{\'a}vez-Brown and Michael A Sopko and J. A. Ortiz Rey},
  journal={Pediatric Drugs},
The treatment of pervasive developmental disorders (PDDs) is a challenging task, which should include behavioral therapy modifications as well as pharmacologic therapy. There has been a lack of data on using medications in children with PDDs until recent years. Within the last 10 years, an increase in clinical research has attempted to provide efficacy and safety data to support the use of medications in children with PDDs. Double-blinded and open-label research of atypical antipsychotics has… 

Prescribing antipsychotics for children and adolescents

Evidence from an increasing number of randomised controlled trials (RCTs) points to therapeutic efficacy with moderate to large effect sizes, however, some RCTs have a small number of participants, are of short duration, and many are industry funded.

[Acute Dystonia due to Aripiprazole Use in Two Children with Autism Spectrum Disorder in the First Five Years of Life].

A review of the literature uncovered limited data regarding the association between acute dystonia and aripiprazole use in ASD children under five years of age, and presented two cases of autistic spectrum disorder children with ages under 5 years that developed acute Dystonia taking aripipsine.

Efficacy of risperidone in managing maladaptive behaviors for children with autistic spectrum disorder: a meta-analysis.

  • Akanksha SharmaS. Shaw
  • Psychology, Medicine
    Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners
  • 2012

Atypical and Typical Antipsychotics in the Schools.

Although these agents, as their name suggests, are most commonly used to alleviate positive, as well as some negative, symptoms of psychotic manifestations, empirical evidence has suggested their efficacy in the treatment of other presentations.

Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents.

Oral risperidone treatment was better than placebo treatment in reducing irritability and other behavioral symptoms associated with autistic disorder in children and adolescents in two well designed short-term trials, with these benefits maintained in those receiving ris peridone for up to 6 months.

Unwanted interactions among psychotropic drugs and other treatments for autism spectrum disorders.

A utism spectrum disorders (ASD) are pervasive neurodevelopmental disorders affecting approximately 1% of children and characterized by varying degrees of deficiencies in social interactions,

Low-Dose Quetiapine for Adolescents With Autistic Spectrum Disorder and Aggressive Behavior: Open-Label Trial

Short-term low-dose quetiapine treatment may reduce aggression levels and improve sleep quality in adolescents with ASD.

Aripiprazole decreases irritability in 12 out of 14 youth with autism spectrum disorders.

An open-label study of aripiprazole in youth with ASDs over a 12 week period, to test its effectiveness and safety in youth 7–14 years of age and confirmed using both the Autismdiagnostic Observation Schedule (ADOS) and the Autism Diagnostic Interview-Revised (ADI-R).

Adjunctive quetiapine may help depression comorbid with pervasive developmental disorders

Aripiprazole in patients with autistic spectrum disorders: a review and case reports

APZ reduces aggression in ASDs and improves qualitative deficits in interpersonal interactions and motivation and causes fewer adverse events compared with other antipsychotics.



Risperidone in children with autism and serious behavioral problems.

Risperidone was effective and well tolerated for the treatment of tantrums, aggression, or self-injurious behavior in children with autistic disorder and the benefit was maintained at six months.

Psychiatry: Role of Risperidone in Children with Autism Spectrum Disorder

Based on the data examined, risperidone appears efficacious and safe for treating certain behavioral aspects of autism including irritability, aggression, hyperactivity, and stereotypy, but does not appear to be as effective for the treatment of the core symptoms of autism.

Use of risperidone in pervasive developmental disorders: a case series.

  • S. FismanM. Steele
  • Psychology, Medicine
    Journal of child and adolescent psychopharmacology
  • 1996
Positive and negative symptoms, as typically characterized in schizophrenia, were both found to improve equally well with risperidone treatment, and a prospective clinical trial with a randomized controlled design is warranted.

Risperidone in the Treatment of Disruptive Behavioral Symptoms in Children With Autistic and Other Pervasive Developmental Disorders

Risperidone was well tolerated and efficacious in treating behavioral symptoms associated with PDD in children and seemed manageable with dose/dose-schedule modification.

A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder.

Olanzapine may be a promising treatment for improving global functioning of PDDs, but the risk of significant weight gain remains a concern.

Atypical antipsychotics in persons with developmental disabilities

The introduction of clozapine spawned the development of several novel antipsychotic agents during the last decade. Compared to traditional agents, these “atypical antipsychotics” demonstrate more

Risperidone in pervasive developmental disorders

This drug profile will review the available data on the use of risperidone in individuals with pervasive developmental disorders and emphasis will be placed on adverse effects associated with risperide in these people.

Genetics of childhood disorders: XLIV. autism, part 3: psychopharmacology of autism.

  • C. McDougleD. Posey
  • Psychology, Medicine
    Journal of the American Academy of Child and Adolescent Psychiatry
  • 2002
The pharmacological management of hyperactivity and impaired attention has proven particularly challenging and lithium, valproic acid, carbamazepine, and gabapentin, have not been reported in well-defined groups of autistic subjects.

Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation.

The data indicate that risperidone is an effective and relatively safe drug for long term treatment of behavioral disruption in autistic children and adolescents.

Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness.

Risperidone shows promise as a treatment in autism, however, withdrawal dyskinesias were noted and the need for further drug treatment and the occurrence of withdrawal Dyskinesia were assessed.